Abstract |
Normal B cells can be induced to express immune costimulatory molecules by activated T cells, and activated CD4 T cells can express CD40 ligand, a molecule that can engage CD40 on the B-cell surface. CD40-CD40 ligand interaction plays an important role in the pathology of certain autoimmune diseases. We report a patient with chronic idiopathic thrombocyopenic purpura ( ITP) who was effectively treated with a single injection of humanized monoclonal antibody to CD40 ligand (E6040). The patient was refractory to steroid therapy, and had baseline platelet counts below 30 x 10(9)/l during the 3-month period before antibody treatment. The patient's platelet counts have increased to more than 100 x 10(9)/l long-term after E6040 administration. Platelet-associated IgG was decreased with thrombocytosis. Compared with the initial period of E6040 administration, the number of anti-GPIIb/IIIa antibody-producing B cells decreased, and proliferative response of autoreactive T cells to GPIIb/IIIa was also improved. A single injection of humanized monoclonal antibody to CD40 ligand may induce T-cell tolerance in patients with ITP.
|
Authors | Shosaku Nomura, Masataka Kuwana, Yasuo Ikeda |
Journal | Autoimmunity
(Autoimmunity)
Vol. 36
Issue 5
Pg. 317-9
(Aug 2003)
ISSN: 0891-6934 [Print] England |
PMID | 14567562
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- CD40 Ligand
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- CD40 Ligand
(immunology, metabolism)
- Humans
- Immunotherapy
- Male
- Middle Aged
- Purpura, Thrombocytopenic, Idiopathic
(immunology, therapy)
- Self Tolerance
- T-Lymphocytes
(immunology)
|